Phentermine
- Generic Name
- Phentermine
- Brand Names
- Adipex-P, Lomaira, Qsymia
- Drug Type
- Small Molecule
- Chemical Formula
- C10H15N
- CAS Number
- 122-09-8
- Unique Ingredient Identifier
- C045TQL4WP
- Background
Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug. It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows this agent to be classified under the Schedule IV drugs (low ...
- Indication
Phentermine is indicated, alone or in combination with topiramate, as a short-term adjunct, not pass a few weeks, in a regimen of weight reduction based on exercise, behavioral modifications and caloric restriction in the management of exogenous obesity for patients with an initial body mass index (BMI) greater than 30 kg/m2 or greater than 27 kg/m2 in prese...
- Associated Conditions
- Obesity
- Associated Therapies
- Chronic Weight Management therapy
Studying the Effects of Phentermine on Eating Behavior
- First Posted Date
- 2013-06-26
- Last Posted Date
- 2017-07-31
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 13
- Registration Number
- NCT01886937
- Locations
- 🇺🇸
The New York State Psychiatric Institute at Columbia University Medical Center, New York, New York, United States
The Effect of Phentermine and B12 on Weight Loss Among Obese Patients
- Conditions
- Interventions
- First Posted Date
- 2012-11-01
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Dr. Michael Lang
- Target Recruit Count
- 22
- Registration Number
- NCT01719185
- Locations
- 🇺🇸
Brody Outpatient of Brody Medical Sciences Module D, Greenville, North Carolina, United States
Effect of Caloric Restriction on Fat Oxidation in Obese Men and Women (Magellan II)
- Conditions
- Interventions
- First Posted Date
- 2012-06-11
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- AdventHealth Translational Research Institute
- Target Recruit Count
- 39
- Registration Number
- NCT01616082
- Locations
- 🇺🇸
Translational Research Institute for Metabolism and Diabetes, Orlando, Florida, United States
Study in Healthy Recreational Polydrug Users to Measure the Abuse Potential of TC-5214
- Conditions
- Interventions
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2012-03-22
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT01500018
Phentermine/Gastric Band Weight Loss Study
- First Posted Date
- 2008-10-13
- Last Posted Date
- 2022-04-21
- Lead Sponsor
- Wake Forest University Health Sciences
- Registration Number
- NCT00771654
A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 756
- Registration Number
- NCT00563368
- Locations
- 🇺🇸
Research Site, Philadelphia, Pennsylvania, United States
Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults
- First Posted Date
- 2007-08-20
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 64
- Registration Number
- NCT00518466
- Locations
- 🇺🇸
VIVUS, Inc., Mountain View, California, United States
A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects
- Conditions
- Interventions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 258
- Registration Number
- NCT00402077
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Cardiovascular System in Obesity: Effect of Treatment
- Conditions
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.